CYPHERPUNK TECHNOLOGIES INC.
Cypherpunk Technologies Inc. (NASDAQ: CYPH) operates as a privacy technology company implementing a digital asset treasury strategy anchored by Zcash, while maintaining ongoing cancer drug development through its subsidiary Leap Therapeutics, Inc. The company's website is located at www.cypherpunktechnologies.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CYPHERPUNK TECHNOLOGIES INC. does
In the company’s own words
Cypherpunk Technologies Inc. (NASDAQ: CYPH) operates as a privacy technology company implementing a digital asset treasury strategy anchored by Zcash, while maintaining ongoing cancer drug development through its subsidiary Leap Therapeutics, Inc. The company's website is located at www.cypherpunktechnologies.com.
The company's primary business focuses on identifying, developing, and investing in privacy-enhancing technologies, with an initial emphasis on the Zcash ecosystem. Zcash is a decentralized blockchain network that enables privacy-preserving transactions through zero-knowledge cryptography, allowing users to conduct shielded transactions where sender, recipient, and transaction amounts remain encrypted. As of March 2026, Cypherpunk held approximately 294,743 ZEC tokens, representing roughly 1.76 percent of total circulating supply, with a stated objective to accumulate holdings representing at least five percent of circulating supply over time. The company competes with exchange-traded products, other digital asset treasury companies, traditional financial firms, and venture capital investors focused on privacy technologies and digital assets.
Through its Leap Therapeutics subsidiary, the company develops biomarker-targeted antibody therapies for cancer treatment. The lead program is sirexatamab (DKN-01), a monoclonal antibody targeting Dickkopf-related protein 1 for colorectal cancer treatment. The company recently completed a Phase 2 study demonstrating improved overall response rates, progression-free survival, and overall survival in patients with high circulating DKK1 plasma levels. A secondary preclinical program, FL-501, targets growth and differentiation factor 15 to treat cachexia-related indications and is being developed through collaboration with Adimab.
The company holds exclusive licensing rights from Eli Lilly and Company covering 26 issued patents and one pending patent application related to sirexatamab composition and use, with base patent terms expiring in 2030. Additional patent families covering biomarker-based patient subpopulations and combination therapies extend protection through 2045. The company operates as a smaller reporting company and is not a shell company. In November 2025, the company changed its name from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc., reflecting its strategic pivot toward privacy technology and digital asset accumulation while maintaining its biotechnology operations under the Leap subsidiary structure.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1509745
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CYPHERPUNK TECHNOLOGIES INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CYPHERPUNK TECHNOLOGIES INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CYPHERPUNK TECHNOLOGIES INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CYPHERPUNK TECHNOLOGIES INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CYPHERPUNK TECHNOLOGIES INC.'s last four quarterly filings that the numbers alone won't show?”